UBS Group
LHDX

UBS Group’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

UBS Group’s Portfolio LHDX Stock Details LHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,877
Closed -$5K – 11539
2022
Q3 		$5K Sell
4,877
-33
-0.7% -$75 ﹤0.01% 9289
2022
Q2 		$9K Buy
4,910
+3,291
+203% +$8K ﹤0.01% 8237
2022
Q1 		$6K Sell
1,619
-153
-9% -$751 ﹤0.01% 9053
2021
Q4 		$15K Buy
1,772
+625
+54% +$3.98K ﹤0.01% 8292
2021
Q3 		$9K Sell
1,147
-1,276
-53% -$10.8K ﹤0.01% 8142
2021
Q2 		$16K Sell
2,423
-652
-21% -$4.11K ﹤0.01% 7604
2021
Q1 		$37K Buy
+3,075
New +$61K ﹤0.01% 6841

Other funds holding LHDX

EV
Eclipse Ventures Palo Alto, California $2.57B AUM
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CWA
Consilio Wealth Advisors Bellevue, Washington $417M AUM 20.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's LHDX Position: Q4 2022 in Review

UBS Group sold out of Lucira Health, Inc. Common Stock (LHDX) in Q4 2022, closing a stake of 4,877 shares — an estimated $5K sold.

UBS Group first reported a position in LHDX in Q1 2021 and held it in 7 quarters. The position peaked at $37K in Q1 2021. 29 funds tracked by Wall St. Rank hold LHDX as of Q4 2022.

  • UBS Group reported no remaining Lucira Health, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 4,877 Lucira Health, Inc. Common Stock shares in Q4 2022, an estimated $5K.
  • UBS Group first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • UBS Group's Lucira Health, Inc. Common Stock position peaked at $37K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.